An off-the-shelf vaccine designed to target the KRAS mutations that drive most pancreatic cancers strengthened immune responses in nearly every patient tested, but it did not significantly delay cancer recurrence in a randomized Phase 2 trial published in Nature Medicine. The University of Colorado Anschutz Medical Campus, one of 24 trial sites, released details of the findings on Nov. 19.
Among 90 vaccinated patients who could be evaluated, 89—98.9%—developed stronger T-cell responses against mutated KRAS, according to Mayo Clinic, which co-led the study with Memorial Sloan Kettering. Median disease-free survival was 23.8 months with the vaccine and 21.2 months with observation alone, a difference that was not statistically significant.
For patients who have completed surgery and chemotherapy for pancreatic cancer, the following months are often spent awaiting the next scan. The vaccine, called camupepimut or ELI-002 7P, is not available outside clinical trials, and this study did not show that it prevents the cancer from returning.
Training T Cells Against Seven KRAS Mutations
KRAS mutations are found in about 90% of pancreatic cancers. The vaccine targets seven common variants and is designed to reach the lymph nodes, where many immune responses begin.
Patients receive four injections—one in each arm and one in each leg—aimed at nearby lymph nodes. Unlike personalized cancer vaccines made from a patient’s own tumor, camupepimut is manufactured in advance and could be given to any patient with a matching mutation.
The vaccine activated both CD4 and CD8 T cells, two types of immune cells that help identify and destroy abnormal cells. Among patients evaluated at least 46 weeks after the study began, 95.5% still had a detectable KRAS-specific response. In a small subset, the immune system also began recognizing cancer targets not included in the vaccine.
Lead author Dr. Ben George, a Mayo Clinic medical oncologist, said the vaccine generated a strong immune response against KRAS mutations in nearly every patient. An earlier version of the vaccine targeting two KRAS mutations was tested in a Phase 1 trial published in 2024.
The Recurrence Result and Its Subgroups
The trial, called AMPLIFY-7P, enrolled 144 adults with stage 1 to 3 pancreatic cancer who had completed surgery and chemotherapy and had no detectable disease. Patients were randomly assigned two to one to the vaccine or observation and followed for a median of 19.4 months, according to 2 Minute Medicine. The hazard ratio for disease-free survival was 0.85, with a p-value of 0.53.
Severe side effects of grade 3 or higher occurred in 10.4% of vaccinated patients and 14.6% of those under observation. Overall survival data are not yet mature.
Some groups fared better in exploratory analyses. Among patients with no detectable circulating tumor DNA, a blood marker of residual cancer, 70% in the vaccine group were alive without recurrence at 18 months, compared with 56% with observation, CU Anschutz reported. Patients who had received radiation had weaker immune responses, and those with stage 3 cancer had poorer outcomes.
Elicio Therapeutics, which developed the vaccine, has emphasized patients whose tumors were completely removed with clear margins—about 84% of the trial. In that group, a post-hoc analysis found a hazard ratio of 0.65, with median disease-free survival of 23.8 months with the vaccine versus 12.8 months with observation, according to CancerNetwork. The company is using that finding to shape its Phase 3 plans. The vaccine group also included more patients whose surgery left cancer cells at the edges—19% versus 10%—a factor known to worsen outcomes.
Open-Label Design and Exploratory Findings
Evidence Check: AMPLIFY-7P was an open-label randomized Phase 2 trial of 144 patients, published in the peer-reviewed journal Nature Medicine. It found strong immune responses and relatively few severe side effects. It did not show that the vaccine significantly delays recurrence, its primary goal. The vaccine was developed by Elicio Therapeutics, a company with a financial stake in the results.
Open-label means patients and doctors knew who received the vaccine. The comparison group received no placebo injection. Subgroup findings, especially those identified after the results were known, can suggest who might benefit but cannot prove it.
A strong immune response is a necessary first step, not proof of clinical benefit. In this trial, immune activation alone did not translate into a clear advantage for the overall study population.
Patients Finishing Pancreatic Cancer Treatment
Pancreatic cancer often returns even after successful surgery and chemotherapy. The five-year relative survival rate across all stages is about 13.7%, according to federal estimates cited by the American Association for Cancer Research.
Patients who have completed treatment can ask their oncologist about the planned Phase 3 trial and other studies for people at high risk of recurrence. Large centers such as Mayo Clinic, Memorial Sloan Kettering, and CU Anschutz participate in many of these trials.
Circulating tumor DNA tests are increasingly used to look for traces of cancer after treatment, but they are not standard for every patient, and coverage varies. Patients can ask whether such testing is appropriate for them and whether their insurer will cover it.
Follow-up scans and visits remain the standard way to monitor for recurrence. New abdominal or back pain, unexplained weight loss, yellowing of the skin or eyes, or new digestive problems should be reported between visits.
The Phase 3 trial is expected to focus on patients whose tumors were completely removed and to use extended dosing. Additional data are expected from that study.
Key Questions Answered
What is the vaccine? Camupepimut, or ELI-002 7P, an off-the-shelf vaccine targeting seven common KRAS mutations in pancreatic cancer.
Did it work? It triggered immune responses in 98.9% of evaluated patients but did not significantly delay recurrence.
What were the recurrence numbers? Median disease-free survival was 23.8 months with the vaccine and 21.2 months with observation.
Was it safe? Severe side effects occurred in 10.4% of vaccinated patients and 14.6% of those under observation.
Can patients get it now? No. It is available only in clinical trials.
What happens next? A larger Phase 3 trial is planned, focusing on patients whose tumors were completely removed.
Also Read
- Cutting food waste starts in the kitchen — and it can go further than we think
- Washington, D.C. Mass Shooting Involving Emergency Physician Shocks Medical Community
- Army Postpones Iowa Lead Azide Detonation to Monday as Communities Near Burlington Prepare for Potential Lead Dust
- Massachusetts Confirms First Pediatric Flu Death of 2026-27 Season, Arriving Six Weeks Earlier Than Last Year


